(Total Views: 552)
Posted On: 09/29/2022 12:32:35 PM
Post# of 154851
Reflections next day on CC: We are in a very strong position and here’s why.
Cyrus is obviously competent and did a thorough cost/benefit analysis which would include getting on the phone to friends in the FDA/BP industry. So what we include and what we exclude as working for us is going to be well informed. I think RTT and Long Haulers fall into this category of up against Remdesivir don’t go there territory until you get an approval. Approval by connections is where we are.
Notice there were no new trail announced which to me means we here at the FDA want you to couple with Pfizer on NASH or somebody else on breast cancer and then we could see our way clear to approval.
Cyrus is obviously competent and did a thorough cost/benefit analysis which would include getting on the phone to friends in the FDA/BP industry. So what we include and what we exclude as working for us is going to be well informed. I think RTT and Long Haulers fall into this category of up against Remdesivir don’t go there territory until you get an approval. Approval by connections is where we are.
Notice there were no new trail announced which to me means we here at the FDA want you to couple with Pfizer on NASH or somebody else on breast cancer and then we could see our way clear to approval.
(0)
(0)
